Some diabetes drugs like Exenatide and Dulaglutide might help people cut down on drinking alcohol or smoking, based on several medical studies.

20

Pro

0

Against

Evidence from Studies

Supporting (1)

20

Community contributions welcome

20

Potential role of glucagon-like peptide-1 (GLP-1) receptor agonists in substance use disorder: A systematic review of randomized trials.

Systematic Review

Human

2024 Nov 1

The study looked at drugs like Exenatide and Dulaglutide in people and found they may help reduce alcohol and nicotine use, which supports the idea that these drugs could help treat addiction.

Contradicting (0)

0

Community contributions welcome

No contradicting evidence found

Gold Standard Evidence Needed

According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.

Source Study

Potential role of glucagon-like peptide-1 (GLP-1) receptor agonists in substance use disorder: A systematic review of randomized trials.

Score: 20

DOI: 10.1016/j.drugalcdep.2024.112424

Similar Assertions

A few small studies have tested diabetes drugs like Exenatide and Dulaglutide in people with addiction, and while there’s not much data yet, it’s an area scientists are starting to explore.

20

0

86%

Diabetes drugs called GLP-1 agonists might help people overcome addictions by reducing how pleasurable substances like alcohol, nicotine, and opioids feel in the brain.

53

0

80%

A type of diabetes drug might help reduce cravings and relapse in addiction by affecting brain signals tied to pleasure and reward — at least in animals.

1

0

79%

Mice given GLP-1 drugs tend to avoid nicotine, suggesting these drugs might reduce the appeal of nicotine.

6

0

73%

For US veterans with type 2 diabetes, starting a GLP-1 drug (like Ozempic) might help lower the chance of developing addiction problems—like with alcohol, drugs, or smoking—over three years compared to starting a different diabetes drug called an SGLT-2 inhibitor.

53

0

73%